Ann Lab Med.  2014 Jan;34(1):66-67. 10.3343/alm.2014.34.1.66.

Response to the Comments on 'Point of Care D-Dimer Testing in the Emergency Department-A Bioequivalence Study' and Erratum to the Results

• Perveen S
• Unwin D
• Shetty AL
• Byth K

• KMID: 1781364
• DOI: http://doi.org/10.3343/alm.2014.34.1.66

Abstract

No abstract available.

MeSH Terms

Female
Fibrin Fibrinogen Degradation Products/*analysis
Humans
Male
Venous Thromboembolism/*diagnosis
Fibrin Fibrinogen Degradation Products

Reference

1. Perveen S, Unwin D, Shetty AL. Point of care D-dimer testing in the emergency department: a bioequivalence study. Ann Lab Med. 2013; 33:34–38. PMID: 23301220.

2. Vossen JA, Albrektson J, Sensarma A, Williams SC. Clinical usefulness of adjusted D-dimer cut-off values to exclude pulmonary embolism in a community hospital emergency department patient population. Acta Radiol. 2012; 53:765–768. PMID: 22761348.

3. Leng O. Application of age-adjusted D-dimer threshold for exclusion thromboembolism (PTE) in older patients: a retrospective study. Acute Med. 2012; 11:129–132. PMID: 22993741.

4. Douma RA, le Gal G, Söhne M, Righini M, Kamphuisen PW, Perrier A, et al. Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: a retrospective analysis of three large cohorts. BMJ. 2010; 340:c1475. PMID: 20354012.

5. Douma RA, van Sluis GL, Kamphuisen PW, Söhne M, Leebeek FW, Bossuyt PM, et al. Clinical decision rule and D-dimer have lower clinical utility to exclude pulmonary embolism in cancer patients. Explanations and potential ameliorations. Thromb Haemost. 2010; 104:831–836. PMID: 20664894.

6. Mochizuki S, Yoshino T, Kojima T, Fuse N, Ikematsu H, Minashi K, et al. Therapeutic significance of a D-dimer cut-off level of >3 μg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab. Jpn J Clin Oncol. 2010; 40:933–937. PMID: 20494948.

7. Duriseti RS. Cost-effectiveness of strategies for diagnosing pulmonary embolism among emergency department patients presenting with undifferentiated symptoms. Ann Emerg Med. 2010; 56:321–332. e10. PMID: 20605261.

8. Sukhu K, Beavis J, Baker PM, Keeling DM. Comparison of an immuno-turbidometric method (STalia D-DI) with an established enzyme linked fluorescent assay (VIDAS) D-dimer for the exclusion of venous thromboembolism. Int J Lab Hematol. 2008; 30:200–204. PMID: 18479298.

9. European Medicines Agency. Guideline on the investigation of bioequivalence. European Medicines Agency. CPMP/EWP/QWP/1401/98 Rev. 1. London: European Medicines Agency;2010. p. 1–27.

10. U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER). Bioavailability and bioequivalence studies for orally administered drug products-general considerations. Rockville, MD: U.S. Department of Health and Human Services FaDA, Center for Drug Evaluation and Research (CDER);2003. p. 1–23.

11. Obuchowski NA, Zhou XH. Prospective studies of diagnostic test accuracy when disease prevalence is low. Biostatistics. 2002; 3:477–492. PMID: 12933593.